Expertise in
15
conditions

Florence Joly-Lobbedez

Caen, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
15
conditions
Caen, FR 
OverviewLocationsClinical Research

Overview

Florence Joly-Lobbedez practices in Caen, France. Ms. Joly-Lobbedez is highly rated in 15 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Autoimmune Hemolytic Anemia, Renal Cell Carcinoma (RCC), Orchiectomy, and Nephrectomy.

Her clinical research consists of co-authoring 326 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Caen, France
Other Locations
Gustave Roussy
Villejuif, France
Marseille, France
Rouen, 76000, France
Irles, France
Paris, France
Clermont-ferrand, 63122, France
Theix, 63122, France
Chilly, France
Francois, France
Lyon, France
51, Avenue Mal De Lattre De Tassigny, Creteil, 94000, France
France
Lille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
Enrollment Status: Recruiting
Publish Date: July 02, 2025
Intervention Type: Radiation
Study Drug: Pursuit of ongoing systemic treatment
Study Phase: Phase 2
Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drugs: Carboplatin-Paclitaxel, Dostarlimab
Study Phase: Phase 3
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy
Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Diagnostic test, Other
Study Phase: Not Applicable
A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin in Combination With Standard Chemotherapy Followed by Niraparib Maintenance Treatment in Platinum-sensitive Ovarian Cancer Patients
A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin in Combination With Standard Chemotherapy Followed by Niraparib Maintenance Treatment in Platinum-sensitive Ovarian Cancer Patients
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Ganetespib, Niraparib, Carboplatin, Paclitaxel, Gemcitabine
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, Cisplatin, Carboplatin, Paclitaxel, Atezolizumab
Study Phase: Phase 3
Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2024
Intervention Type: Drug
Study Drugs: OSE2101, Pembrolizumab [Keytruda]
Study Phase: Phase 2
A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months
A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Niraparib, Gemcitabine, Pegylated liposomal doxorubicin, Atezolizumab
Study Phase: Phase 3
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Enrollment Status: Unknown
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drugs: AZD2014, Anastrozole
Study Phase: Phase 1/Phase 2
MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?
MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?
Enrollment Status: Completed
Publish Date: October 18, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer
Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer
Enrollment Status: Completed
Publish Date: January 11, 2023
Intervention Type: Other
Study Phase: Not Applicable
EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer
EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 04, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy
A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy
Enrollment Status: Completed
Publish Date: July 09, 2020
Intervention Type: Other
Study Phase: Phase 2
Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep
Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep
Enrollment Status: Completed
Publish Date: March 09, 2020
Intervention Type: Drug, Other
Study Phase: Not Applicable
Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer
Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer
Enrollment Status: Completed
Publish Date: February 07, 2020
Intervention Type: Other
Study Phase: Not Applicable
Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria
Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria
Enrollment Status: Terminated
Publish Date: August 06, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 17 Less Clinical Trials

326 Total Publications

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Joly-Lobbedez's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 47 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile